First-in-Human Phase I Trial of TPST-1120, an inhibitor of PPAR α, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

CONCLUSIONS: TPST-1120 was well tolerated as monotherapy and in combination with nivolumab and the combination showed preliminary evidence of clinical activity in PD-1 inhibitor refractory and immune compromised cancers.PMID:38551394 | DOI:10.1158/2767-9764.CRC-24-0082

Source: Cell Research - March 29, 2024 Category: Cytology Authors: Mark Yarchoan John D Powderly Bruno R Bastos Thomas B Karasic Oxana V Crysler Pamela N Munster Meredith A McKean Leisha A Emens Yvonne M Saenger Yasser Ged Robert Stagg Steven Smith Chan C Whiting Anne Moon Peppi Prasit Yonchu Jenkins Nathan Standifer Tho Source Type: research